Panel To Ponder Nuplazid's Clinical Meaningfulness
This article was originally published in Scrip
Executive Summary
The FDA is grappling with how to characterize the clinically meaningfulness of Acadia Pharmaceuticals Inc.'s data from its single Phase III study of Nuplazid (pimavanserin), a drug intended to treat psychosis associated with Parkinson's disease, and plans to seek help from a panel of advisers on March 29 to figure it out.